Drug Use Investigation of Selara Tablets (an Investigation for Chronic Heart Failure)

CompletedOBSERVATIONAL
Enrollment

1,165

Participants

Timeline

Start Date

July 5, 2017

Primary Completion Date

July 15, 2020

Study Completion Date

July 15, 2020

Conditions
Chronic Heart Failure
Interventions
DRUG

Eplerenone

"In adults, usually, administer the initial dose of 25 mg once daily according to the patient's serum potassium level and conditions, increase dosage up to 50 mg once daily after 4 week; patients with moderate renal impairment should start with 25 mg every other day and the maximum dosage should be 25 mg once daily.~Also, dose should be reduced or interrupted according to serum potassium level and patient's conditions."

Trial Locations (1)

Unknown

Pfizer Local Country Office, Tokyo

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT03342690 - Drug Use Investigation of Selara Tablets (an Investigation for Chronic Heart Failure) | Biotech Hunter | Biotech Hunter